SCHEMBL21597774

SCHEMBL21597774

CCOC(=O)C1CCCc2c1sc(NC(=O)C1CC1)c2C(=O)NCC1CC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 6/20 0.45
CNR1 P21554 2/20 0.45
MAPT P10636 7/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 2/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HSD17B10 Q99714 1/20 0.41
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
HIF1A Q16665 1/20 0.40
TSHR P16473 1/20 0.40
FLT3 P36888 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
TP53 P04637 1/20 0.37
ALOX15 P16050 1/20 0.37
MAPK14 Q16539 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21604195 0.88 CNR2 (0.45) CNR2CNR1MAPTALDH1A1HPGD
SCHEMBL21597165 0.88 CNR2 (0.45) CNR2CNR1MAPTALDH1A1HPGD
SCHEMBL21597806 0.86 CNR2 (0.46) CNR2CNR1MAPTALDH1A1KDM4E
SCHEMBL21597670 0.86 MAPT (0.47) CNR2CNR1MAPTALDH1A1HPGD
SCHEMBL21603880 0.84 CNR2 (0.41) CNR2CNR1MAPTALDH1A1HPGD
SCHEMBL21597537 0.83 ALDH1A1 (0.42) CNR2MAPTALDH1A1HPGDMAPK1
SCHEMBL21597282 0.83 CNR2 (0.47) CNR2CNR1MAPTALDH1A1KDM4E
SCHEMBL21597739 0.82 MAPT (0.47) MAPTALDH1A1HPGDMAPK1KMT2A
SCHEMBL21597094 0.80 CNR2 (0.45) CNR2CNR1MAPTALDH1A1KDM4E
SCHEMBL21597174 0.80 CNR2 (0.48) CNR2CNR1MAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
EP-3810606-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2021-04-28 EP disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 CNR2 1326/4885CNR1 823/4885MAPT 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.